c-Met/HGFR

Related Products

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

c-Met/HGFR Related Products (197)
Recombinant Proteins (15)
Antibodies (7)

By Effects:	Inhibitors (182) Agonist (1) Degraders (5) Activators (3) Inducer (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-18307

SYN1143	Inhibitor	99.36%
SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC₅₀s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on Lck, Tie2, Src, and BTK with IC₅₀s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated.

HY-N6797

Meleagrin	Inhibitor	≥99.0%
Meleagrin is a roquefortine C-derived alkaloid produced by fungi of the genus Penicillium and has antimicrobial and anti-proliferative activities. Meleagrin is a class of FabI inhibitor. Meleagrin is a lead c-Met inhibitory entity useful for the control of c-Met-dependent metastatic and invasive breast malignancies.

HY-157148

1D228	Inhibitor
1D228 is a c-Met/TRK inhibitor with antitumor activity. 1D228 inhibits cyclin D1 to induce G0/G1 arrest and inhibit cancer cell proliferation and migration. 1D228 can be used in the study of gastric, liver and vascular tumors.

HY-14721R

Tepotinib (Standard)	Inhibitor
Tepotinib (Standard) is the analytical standard of Tepotinib. This product is intended for research and analytical applications. Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation. Tepotinib has antitumor effects.

HY-13016R

Cabozantinib (Standard)	Inhibitor
Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2/KDR/Flk-1 and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.

HY-164884

MetsiRNA-3	Inhibitor
MetsiRNA-3 is a Small Interfering RNA (siRNA) targeting Met for knocking down the Met gene.

HY-13404A

Capmatinib dihydrochloride	Inhibitor
Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC₅₀=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase.

HY-10261D

Afatinib oxalate	Inhibitor
Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC₅₀ values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.

HY-13016A

Cabozantinib hydrochloride	Inhibitor
Cabozantinib hydrochloride is a potent and orally active inhibitor of VEGFR2/KDR/Flk-1 and MET, with IC₅₀ values of 0.035 and 1.3 nM, respectively. Cabozantinib hydrochloride displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib hydrochloride shows antiangiogenic activity. Cabozantinib hydrochloride disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.

HY-101773

c-Met-IN-2	Inhibitor
c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC₅₀ of 0.6 nM, with antitumor activity.

HY-50878B

Crizotinib acetate	Inhibitor
Crizotinib (PF-02341066) acetate is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC₅₀s of 20 and 8 nM, respectively. Crizotinib acetate inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC₅₀s of 24 and 11 nM in cell-based assays, respectively. Crizotinib acetate is also a ROS1 inhibitor. Crizotinib acetate has effective tumor growth inhibition.

HY-10206A

Amuvatinib hydrochloride	Inhibitor
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity.

HY-12017B

PF-04217903 phenolsulfonate	Inhibitor
PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with K_i of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties.

HY-152849

Boditrectinib	Inhibitor
Boditrectinib is a potent tyrosine kinase inhibitor. Boditrectinib serves as an antineoplastic agent. Boditrectinib is useful in the research of cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

HY-148811

Zurletrectinib	Inhibitor
Zurletrectinib is a potent tyrosine kinase inhibitor. Zurletrectinib serves as an antineoplastic agent. Zurletrectinib can used for research of preventing TRK-mediated related diseases, such as tumors.

HY-152852

Mefatinib free base	Inhibitor	99.40%
Mefatinib free base is a potent tyrosine kinase inhibitor with antineoplastic activity.

HY-152852A

Mefatinib	Inhibitor	98.90%
Mefatinib is a potent tyrosine kinase inhibitor with antineoplastic activity.

HY-152849A

Boditrectinib oxalate	Inhibitor
Boditrectinib oxalate is a potent tyrosine kinase inhibitor. Boditrectinib oxalate serves as an antineoplastic agent. Boditrectinib oxalate is useful in the research of cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

HY-148793

Resencatinib	Inhibitor
Resencatinib is a potent tyrosine kinase inhibitor with antineoplastic activity. Resencatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14721A

Tepotinib hydrochloride	Inhibitor
Tepotinib (EMD-1214063) hydrochloride is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib hydrochloride inhibits c-Met phosphorylation and induces autophagy. Tepotinib hydrochloride has antitumor effects.

Name
Email *

	Sorry, but the email address you supplied was invalid.

c-Met/HGFR

c-Met/HGFR

c-Met/HGFR Related Products (197)

Recombinant Proteins (15)

Antibodies (7)

c-Met/HGFR Related Products (197):